Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837902 | 0.84 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL2837905 | 0.84 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL16096925 | 0.80 | GAA (0.43) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL2336247 | 0.75 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL12245583 | 0.75 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL2336250 | 0.75 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL4255366 | 0.74 | SMN1; SMN2 (0.64) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL4255365 | 0.74 | SMN1; SMN2 (0.64) | RAB9ASMN1; SMN2NPC1GAAPLA2G1B | |
| SCHEMBL28364138 | 0.73 | ALDH1A1 (0.49) | RAB9ASMN1; SMN2NPC1CYP1A2ALDH1A1 | |
| SCHEMBL23501390 | 0.72 | MAPT (0.36) | RAB9ASMN1; SMN2NPC1GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9090625-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Medicis Phamaceutical Corporation (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2074128-B1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | MEDICIS PHARMACEUTICAL CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8455512-B2 | Therapeutic pyrazolyl thienopyridines | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2074128-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008047198-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | RAB9A 1775/4885SMN1; SMN2 3190/4885NPC1 2954/4885 |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | RAB9A 1775/4885SMN1; SMN2 3190/4885NPC1 2954/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | RAB9A 1775/4885SMN1; SMN2 3190/4885NPC1 2954/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | RAB9A 1775/4885SMN1; SMN2 3190/4885NPC1 2954/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | RAB9A 3798/4885SMN1; SMN2 3842/4885NPC1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.